drugset / Trial / NCT01763307

A Study to Examine the Effect of Reconval K1 Cream to Prevent Skin Toxicity From EGFRI

NCT01763307

Phase 2 Completed 18 enrolled Hadassah Medical Organization
RandomizedSingle-groupDouble-blindTreatment

Summary

Vitamin K1 cream may prevent papulopustular rash induced by EGFRI given to metastatic colorectal cancer patients. This study will prospectively accrue metastatic colorectal patients receiving EGFRI and treat with reconval cream half face versus placebo cream half face to study whether Vitamin k1 cream can prevent the typical skin eruption caused by EGFRI.

Timeline

Start
2013-01
Primary completion
2014-01
Completion
2018-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Vitamin K Unknown

Indications